See What HealthDay Can Do For You
Contact Us

Intracytoplasmic Sperm Injection Rates Have Doubled

But the procedure is not always tied to better outcomes

Intracytoplasmic Sperm Injection Rates Have Doubled

WEDNESDAY, Jan. 21, 2015 (HealthDay News) -- Although use of intracytoplasmic sperm injection (ICSI) has doubled in the past decade, the procedure is not always associated with better outcomes, according to a new study from the U.S. Centers for Disease Control and Prevention. The findings were published in the Jan. 20 issue of the Journal of the American Medical Association.

In conducting the study, the team of researchers, led by the CDC's Sheree Boulet, Dr.P.H., M.P.H., analyzed 1,395,634 fresh in vitro fertilization (IVF) cycles reported to the U.S. National Assisted Reproductive Technology Surveillance System between 1996 and 2012.

Of these IVF cycles, 65.1 percent involved ICSI and 35.8 percent involved male infertility. Among fresh IVF cycles, ICSI use in the United States increased from 36.4 percent in 1996 to 76.2 percent in 2012, the researchers found. In cases involving men with male infertility, ICSI use jumped from 76.3 percent in 1996 to 93.3 percent by 2012. Among men who were not infertile, ICSI use rose from 15.4 to 66.9 percent.

Between 2008 and 2012, 35.7 percent of fresh IVF cycles involved male infertility. The researchers noted that when male infertility was not an issue, using ICSI in an IVF procedure was tied to a slight drop in implantation, pregnancy, live birth, and low birth weight rates, compared to using conventional IVF.

Abstract
Full Text

Physician's Briefing